BioStock: CombiGene on the first in vivo study in the lipodystrophy project CGT2

CombiGene reaches a new milestone in its CGT2 project aimed at developing a gene therapy treatment for partial lipodystrophy. A first selection of drug candidates has been made in in vitro experiments with liver cells and the biotechnology company is now taking the next step by initiating in vivo studies to evaluate which protein expression can be achieved in experimental models. BioStock reached out to CombiGene’s CEO Jan Nilsson to learn more about the goal of initiating proof-of-concept studies during 2021.

Read the full interview with CombiGene's CEO Jan Nilsson at biostock.se:

https://www.biostock.se/en/combigene-on-the-first-in-vivo-study-in-the-lipodystrophy-project-cgt2/

This is a pressrelease from BioStock - Connecting Innovation & Capital. https://www.biostock.se/